Tasosartan
Chemical compound
- N/A
- C09CA05 (WHO)
- Withdrawn
- 2,4-dimethyl-8-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
- 145733-36-4 Y
- 60919
- 6898
- DB01349 Y
- 54890 N
- 48G92V856H
- DTXSID40163148
Tasosartan is an angiotensin II receptor antagonist.
It was withdrawn from FDA review by the manufacturer after phase III clinical trials showed elevated transaminases (a sign of possible liver toxicity) in a significant number of participants given the drug.[1][2]
References
- v
- t
- e
Antihypertensive drugs acting on the renin–angiotensin system (C09)
("-pril")
- Sulfhydryl-containing: Captopril
- Rentiapril
- Zofenopril
- Dicarboxylate-containing: Enalapril#
- Benazepril
- Cilazapril
- Delapril
- Imidapril
- Lisinopril (+amlodipine, +HCT)
- Moexipril
- Perindopril (+indapamide)
- Quinapril (+HCT)
- Ramipril
- Spirapril
- Temocapril
- Trandolapril
- Phosphonate-containing: Ceronapril
- Fosinopril (+HCT)
- Other/ungrouped: Alacepril
("-sartan")
("-kiren")
- Gemopatrilat
- Ilepatril
- Omapatrilat
- Sampatrilat
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e